Pharma BD Deal Intelligence

Roche Holding AG / Foundation Medicine, Inc.

2018 · Acquisition/Merger · $5.3B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Worked — the deal delivered on its rationale.

Roche acquired the remaining ~43% of Foundation Medicine it did not already own for approximately $2.4 billion ($137 per share), implying a total equity value of ~$5.3 billion. The deal gave Roche full control of FMI's comprehensive genomic profiling platform, FoundationOne CDx, to pair diagnostics with its oncology therapeutics.

Key facts

Announced Jun 19, 2018
Closed Jul 31, 2018
Deal value $5.3B
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Solid tumors (pan-cancer genomic profiling), Hematologic malignancies, Companion diagnostics
Key assets FoundationOne CDx (FDA-approved comprehensive genomic profiling test), FoundationOne Liquid CDx (liquid biopsy platform), FoundationOne Heme (hematologic malignancies profiling), Genomic profiling database (300,000+ patient samples), Companion diagnostic development partnerships, CLIA-certified, CAP-accredited laboratory
Mechanism Next-generation sequencing (NGS) comprehensive genomic profiling, Circulating tumor DNA liquid biopsy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals